ONEOK Announces Higher Full-Year 2025 Earnings: Net Income up 11%, Adjusted EBITDA up 18% ONEOK Announces 2026 Financial Guidance TULSA, Okla., Feb. 23, 2026 (GLOBE NEWSWIRE) -- ONEOK, Inc. (NYSE: OKE) today announced fourth-quarter and full-year 2025 results and 2026 financial guidance. Unless otherwise noted, all results are compared with the same periods in 2024. Fourth-Quarter 2025 Results: Net income of $978 million, resulting in $1.55 per diluted share.Adjusted EBITDA of $2.15 billion.15% increase in Rocky Mountain region NGL raw feed throughput volumes.3% increase in Rocky Moun...
Occidental Announces Cash Tender Offers and Consent Solicitations for Certain of its Senior Notes and Debentures HOUSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- (NYSE: OXY) today announced that it has commenced offers to purchase for cash (collectively, the “Tender Offers” and each a “Tender Offer”) its outstanding senior notes and debentures listed in the table below and Consent Solicitations (as defined below) with respect to certain series of such senior notes and debentures, upon the terms and conditions described in Occidental’s Offer to Purchase and Consent Solicitation Statement, dated...
Occidental Announces Fourth Quarter 2025 Results HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- (NYSE: OXY) today announced its fourth quarter 2025 financial results. The earnings release and accompanying financial schedules can be accessed via the section of the company’s website at . The earnings release is also available on the U.S. Securities and Exchange Commission’s website at sec.gov. The company will hold a conference call to discuss the results on Thursday, February 19, 2026, at 1 p.m. Eastern/12 p.m. Central. The conference call may be accessed by calling 1-866-871-6512 (internat...
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting BERKELEY HEIGHTS, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company developing differentiated therapies for retinal diseases, today announced that clinical data from its Phase 1 study of TH103 will be presented at the 49th Annual Meeting of the Macula Society, taking place February 25-28 in San Diego, California. TH103 is a novel investigational therapy engineered by VEGF scientific pioneer Dr. Napoleone Ferrara to...
ONEOK Announces Board of Directors Additions Mark A. McCollum and Precious Williams Owodunni Join ONEOK Board of Directors TULSA, Okla., Jan. 26, 2026 (GLOBE NEWSWIRE) -- The board of directors of ONEOK, Inc. (NYSE: OKE) elected Mark A. McCollum and Precious Williams Owodunni as independent directors to the board, effective January 23, 2026. McCollum, 66, is the retired president and chief executive officer of Weatherford International plc, having led the company from April 2017 through June 2020. Before joining Weatherford, he served as executive vice president and chief financial...
ONEOK Increases Quarterly Dividend 4% TULSA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The board of directors of ONEOK, Inc. (NYSE: OKE) today increased its quarterly dividend to $1.07 per share, an increase of 4%. This increase results in an annualized dividend of $4.28 per share. The dividend is payable Feb. 13, 2026, to shareholders of record at the close of business Feb. 2, 2026.----------------------------------------------------------------------------------------------------------------At ONEOK (NYSE: OKE), we deliver energy products and services vital to an advancing world. We are a l...
ONEOK Schedules Fourth-quarter and Year-end 2025 Conference Call and Webcast TULSA, Okla., Jan. 20, 2026 (GLOBE NEWSWIRE) -- ONEOK, Inc. (NYSE: OKE) will release fourth-quarter and year-end 2025 earnings after the market closes on Feb. 23, 2026. Members of ONEOK’s management team will participate in a conference call the following day. What: ONEOK fourth-quarter and year-end 2025 earnings conference call and webcast When: 11 a.m. Eastern, Feb. 24, 2026 10 a.m. Central Where: 1) Phone conference call dial 800-225-9448, conference ID: OKE4Q25 2) Log on to the webcast at If you are una...
Occidental to Announce Fourth Quarter Results Wednesday, February 18, 2026; Hold Conference Call Thursday, February 19, 2026 HOUSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- (NYSE: OXY) will announce its fourth quarter 2025 financial results after close of market on Wednesday, February 18, 2026, and will hold a conference call to discuss the results on Thursday, February 19, 2026, at 1 p.m. Eastern/12 p.m. Central. The conference call may be accessed by calling 1-866-871-6512 (international callers dial 1-412-317-5417) or via webcast at . Participants may pre-register for the conference call ...
Occidental Completes Sale of OxyChem HOUSTON, Jan. 02, 2026 (GLOBE NEWSWIRE) -- (NYSE: OXY) announced today it has completed the sale of its chemical business, OxyChem, to Berkshire Hathaway (NYSE: BRK.A, BRK.B) for $9.7 billion in cash, subject to customary purchase price adjustments. “This transaction accelerates our strategy to strengthen Occidental’s balance sheet and focus on our deep and diverse oil and gas portfolio which we have transformed over the last decade. We expect to operate our high-return oil and gas assets to deliver long-term value while driving innovation across our...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.